Volume 30, Number 2—February 2024
CME ACTIVITY - Synopsis
Multicenter Retrospective Study of Invasive Fusariosis in Intensive Care Units, France
Jordane Demonchy, Lucie Biard, Raphaël Clere-Jehl, Florent Wallet, Djamel Mokart, Anne-Sophie Moreau, Laurent Argaud, Camille Verlhac, Frédéric Pène, Alexandre Lautrette, Naïke Bige, Audrey de Jong, Emmanuel Canet, Jean-Pierre Quenot, Nahéma Issa, Yoann Zerbib, Inès Bouard, Muriel Picard, and Lara Zafrani
Table 3
Characteristics of Fusarium infections and co-infections in among 55 patients in a multicenter retrospective study of invasive fusariosis in intensive care units, France
| Infections and co-infections | No. (%) patients | |
|---|---|---|
| Fusariosis diagnosis | ||
| Probable | 32 (58) | |
| Proven |
23 (42) |
|
| Fusarium species | ||
| Fusarium spp. | 38 (69) | |
| F. oxysporum | 5 (9) | |
| F. proliferatum | 4 (7) | |
| F. solani | 3 (5) | |
| F. fujikuroi | 2 (4) | |
| F. dimerum | 1 (2) | |
| F. monoliforme | 1 (2) | |
| F. keratoplasticum |
1 (2) |
|
| Mycologic diagnosis | ||
| Mycologic culture of biologic samples* | 55 (100) | |
| Pathologic examination of biopsies† | 10 (18) | |
| Positive serum galactomannan |
15 (27) |
|
| Time of diagnosis from intensive care admission | ||
| Before admission | 12 (22) | |
| Day of admission | 12 (22) | |
| After admission |
29 (53) |
|
| Clinical manifestation | ||
| Disseminated infection | 12 (22) | |
| Skin lesions | 14 (25) | |
| Pneumonia | 42 (76) | |
| Sinusitis | 3 (5) | |
| Arthritis | 3 (5) | |
| Infection of pancreatic fluid collections |
1 (2) |
|
| Thoracic computed tomography patterns of pneumonia, n = 37 | ||
| Pulmonary consolidations | 16 (43) | |
| Nodules and micronodules | 12 (32) | |
| Excavated pulmonary lesions | 3 (8) | |
| Ground glass opacities | 9 (24) | |
| Pleural effusion | 6 (16) | |
| Missing data |
5 (14) |
|
| Co-infections | ||
| Bacterial | 32 (58) | |
| Viral | 19 (35) | |
| Fungal |
27 (49) |
|
| Antifungal treatment‡ | ||
| Monotherapy | 46 (84) | |
| Voriconazole | 23 (42) | |
| Amphotericin B | 21 (38) | |
| Isavuconazole | 1 (2) | |
| Terbinafine | 1 (2) | |
| Combination therapy | ||
| Voriconazole + amphotericin B | 11 (20) | |
| Isavuconazole + micafungin | 1 (2) | |
| None | 4 (7) | |
| Missing data |
1 (2) |
|
| Granulocyte colony-stimulating factor |
12 (22) |
|
| Surgical debridement of localized infection |
7 (13) |
|
| Response to therapy | ||
| Progression | 28 (51) | |
| Partial or complete | 14 (25) | |
| Missing data | 13 (24) | |
*Biologic samples included blood cultures, skin biopsies, sputum, bronchoalveolar lavage fluid, sinus aspirate samples, joint fluid, and pancreatic fluid collections. †Pathologic examination of skin or sinus biopsies in which Fusarium are seen and accompanied by tissue damage. ‡Some patients first received a monotherapy and then a combination of 2 drugs because of refractory disease.
Page created: November 30, 2023
Page updated: January 22, 2024
Page reviewed: January 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.